MiRaDor Trial Marks First-Ever Joint Effort by MEDSIR and Oncoclinicas & Co in Pioneering Breast Cancer Research

MEDSIR presented the design of the MiRaDor trial, a proof-of-concept study, conducted in collaboration with Oncoclínicas & Co, which aims to evaluate the usefulness of ctDNA analysis to detect minimal residual disease in patients who had hormone receptor positive/HER2 negative early breast cancer and are at high risk of relapse.